Cell Therapy News/Articles, page-3905

Senate committee hearing on Review of Operation Warp Speed: Researching, Manufacturing, & Distributing a Safe & Effective Coronavirus Vaccine. Date: Thursday, July 2, 2020

https://www.appropriations.senate.gov/hearings/review-of-operation-warp-speed-researching-manufacturing-and-distributing-a-safe_effective-coronavirus-vaccine

The Honorable Francis S. Collins, M.D., Ph.D.DirectorNational Institutes of Health speaks on treatments throughout but particular of note is at the 2hour 59 min mark:

Notes Remdesivir and Dex "Not nearly enough"

Francis S. Collins on trials - "If I had to pick one I think the Monoclonal antibody cocktails have a lot going for them cause we know they worked for ebola"


Our friends at Osiris filed this now expired Patent on in 1998 - https://patentimages.storage.googleapis.com/70/11/00/e32a2260ca5a0a/US5837539.pdf
https://patents.google.com/patent/US5837539A/en

The invention relates to isolated human mesenchymal stem cells, a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. mesenchymal stem cells or "MSCs"), and characterization of (including by cytokine expression profiling) and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Further disclosed are monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.